LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRXBiotechnology
-$0.39 today
- Market cap
- $1.30B
- Beta
- 0.71
- P/E (TTM)
- -21.4
- EPS (TTM)
- -$1.39
Volume 0.36M
Average 0.23M
LBRX Total Debt
Short-term and long-term borrowings combined.
LB Pharmaceuticals Inc Common StockNASDAQ: LBRX
Total Debt · Q1 FY2026 · quarter ended Mar 2026
Total debt falls 7.7% from a year ago
Total debt stood at $3.47M at the end of Q1 FY2026, down 7.7% from a year earlier and down 2.8% from the prior quarter. Over 3 fiscal years it compounded at -47.1% a year.
Context
- Total debt amounted to 0.9% of total assets at the end of Q1 FY2026, down 18.7 pp from a year earlier.
- Total debt increased in 1 of the last 3 fiscal years.
What to watch
Whether total debt keeps falling in the next quarterly balance sheet after a -7.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Debt history
USD · from the balance sheet
- Latest · FY2025
- 3.57M USD
- Year-over-year change
- -3.6%
- 3-year CAGR
- -47.1%
| Period | Period end | Total Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.57M | -3.6% |
| FY2024 | 2024-12-31 | 3.7M | — |
| FY2023 | 2023-12-31 | 0 | -100.0% |
| FY2022 | 2022-12-31 | 24.15M | — |
Total Debt vs competitors
How LBRX compares with its peers on the latest reported figures
- LBRX's Mar 2026 total debt of $3.47M is the 8th highest of the 10 companies compared; the peer median is $10.8M.
- Its year-over-year change of -7.7% is the 3rd highest of 9, against a peer median of -23.5%.
- Total debt amounts to 0.9% of total assets for LBRX, versus a peer median of 2.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $71.74M | — | — | 0.1% | |
| Sep 2026 | $57.32M | +4.6% | -5.6% | 3.2% | |
DFTXDefinium Therapeutics, Inc. | Sep 2026 | $36.66M | -9.2% | — | 3.4% |
| Jun 2026 | $27.51M | -40.9% | -15.2% | 2.4% | |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $10.8M | +37.8% | +3.2% | 2.2% |
| Mar 2026 | $5.69M | -78.5% | -62.3% | 2.1% | |
| Mar 2026 | $5.59M | -12.6% | -2.6% | 1.3% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $3.47M | -7.7% | -47.1% | 0.9% |
| Mar 2026 | $432K | -34.3% | — | 0.2% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $410K | -56.3% | -61.6% | 0.3% |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding LBRX) | $10.8M | -23.5% | -10.4% | 2.1% | |
Competitors are the stored peer set for LBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRX
Intrinsic Alpha fair value
Locked
Current Price
$40.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.